Product Information
IMVEXXY 4 MCG STARTER PACK is a brand product labeled by Mayne Pharma, priced at $27.1090 per EA under NDC 68308074718. Its NADAC has been published 99 times since Nov 13, 2024.
FDA first approved this application on May 29, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the estradiol market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
4 ug/1
Manufacturer
Mayne PharmaNDC
68308074718
Classification
Brand
Dosage Form
INSERT
Route
VAGINAL
Effective Date
6/1/2026
Active Ingredients
ESTRADIOLApproval Type
New Drug (NDA)
FDA Application
NDA208564FDA Approved
5/29/2018
TE Code
AB
On Market Since
5/3/2024
Pharmacological Classes
Price Statistics
The NADAC for IMVEXXY 4 MCG STARTER PACK has been published 99 times since Nov 13, 2024, and over the history we have for it it has risen 4.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $27.1090 per EA |
|---|---|
| All-time high | $27.1090 (Sep 30, 2026) |
| All-time low | $25.8181 (May 20, 2026) |
| 52-week high | $27.1090 |
| 52-week low | $25.8181 |
| Median price | $25.8732 |
| Average price | $26.0874 |
| Largest weekly change | +5.0% (Jun 3, 2026) |
| Weeks tracked | 99 |
| Tracking since | Nov 13, 2024 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mayne Pharma manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
estradiol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Estrogen class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of IMVEXXY 4 MCG STARTER PACK?
The current National Average Drug Acquisition Cost (NADAC) for IMVEXXY 4 MCG STARTER PACK, manufactured by Mayne Pharma, is $27.1090 per EA (NDC 68308074718), effective Sep 30, 2026.
How has the price of IMVEXXY 4 MCG STARTER PACK changed over time?
Over the history we have for it, the NADAC for IMVEXXY 4 MCG STARTER PACK has risen 4.6%. It has been tracked across 99 weekly CMS publications since Nov 13, 2024.
What are the highest and lowest recorded NADAC prices for IMVEXXY 4 MCG STARTER PACK?
Since Nov 13, 2024, the NADAC for IMVEXXY 4 MCG STARTER PACK has ranged from a low of $25.8181 (May 20, 2026) to a high of $27.1090 (Sep 30, 2026), with a median of $25.8732 per EA.
Are there cheaper alternatives to IMVEXXY 4 MCG STARTER PACK?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, IMVEXXY 4 MCG MAINTENANCE PACK, is $27.0962 per EA — about 0% below IMVEXXY 4 MCG STARTER PACK.
Who manufactures IMVEXXY 4 MCG STARTER PACK?
IMVEXXY 4 MCG STARTER PACK (NDC 68308074718) is labeled by Mayne Pharma, and CMS classifies it as a brand product.